UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of May 2024
Commission
File Number: 001-40678
EUDA
Health Holdings Limited
(Exact
Name of Registrant as Specified in its Charter)
1
Pemimpin Drive #12-07
One
Pemimpin Singapore 576151
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: +65 6268 6821
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report
to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that
the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on EDGAR.
As
previously announced, EUDA Health Holdings Limited ( “EUDA” and the “Company”) entered into a Share Purchase
Agreement with certain persons named therein (the “Share Purchase Agreement”) for the acquisition of all outstanding shares
of Fortress Cove Limited, a British Virgin Islands company which is the sole legal and beneficial owner of the entire share capital of
CK Health Plus Sdn Bhd, a Malaysian company (“CK Health”) in the direct sale business of holistic wellness consumer products
in Malaysia, for an aggregate consideration of 10,000,000 newly issued ordinary shares of the Company. The acquisition closed on May
8, 2024, and the Company issued a press release announcing the completion of the transaction.
A
copy of the press release is attached hereto as 99.1, and is incorporated by reference.
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
Dated:
May 8, 2024 |
|
|
|
|
|
EUDA
Health Holdings Limited |
|
|
|
|
By: |
/s/
Wei Wen Kelvin Chen |
|
Name: |
Wei
Wen Kelvin Chen |
|
Title: |
Chief
Executive Officer |
Exhibit
99.1
EUDA
Health Holdings Limited Completes Acquisition of CK Health Plus Sdn Bhd, Expanding into Direct Selling Holistic Wellness Products in
Southeast Asia
Singapore,
May 08, 2024 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (“EUDA” or
the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that
operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, proudly announces
the successful completion of its acquisition of CK Health Plus Sdn Bhd (“CK Health”)
today. This strategic move marks an expansion of EUDA’s presence in Malaysia and underscores
its commitment to revolutionizing the healthcare landscape in the region.
CK
Health is a direct seller of holistic wellness consumer products in Malaysia, committed to delivering high-quality products that promote
holistic well-being. With this acquisition, EUDA gains access to CK Health’s distribution network, customer base, and expertise
in the wellness industry.
EUDA’s
CEO Dr Kelvin Chen expressed excitement about the acquisition, stating, “We are thrilled to welcome CK Health into the EUDA family.
This acquisition aligns seamlessly with our mission to empower individuals to lead healthier lives through innovative technology and
holistic wellness solutions. Together, we will leverage our combined strengths to drive positive health outcomes and create lasting impact
in the communities we serve.”
Management
believes key benefits and synergies resulting from the acquisition include:
1.
Market Expansion: EUDA’s acquisition of CK Health provides entry into the Malaysian market, a key strategic move that enhances
the Company’s regional presence and accelerates its growth trajectory.
2.
Diversification of Product Portfolio: By integrating CK Health’s range of holistic wellness products, EUDA enriches its product
offering, catering to a broader spectrum of health needs and preferences.
3.
Enhanced Distribution Channels: CK Health brings a network of distributors and retailers, enabling EUDA to reach a wider audience and
drive market penetration effectively.
4.
Complementary Expertise: The combination of EUDA’s technological prowess and CK Health’s industry knowledge creates a synergistic
partnership poised for innovation and excellence in the health and wellness sector.
EUDA
remains committed to leveraging this strategic acquisition to drive value for its stakeholders, including customers, partners, and shareholders.
With a shared vision for empowering individuals to take control of their health and well-being, EUDA and CK Health are poised to lead
the charge towards a healthier, more vibrant Southeast Asia.
For
more information about EUDA Health Holdings Limited and its innovative healthcare solutions, please visit www.euda.com.
About
EUDA Health Holdings Limited
EUDA
Health Holdings Limited, is a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare
ecosystem aimed at making healthcare affordable and accessible, and improving the patient experience by delivering better outcomes through
personalized healthcare. The company’s proprietary unified AI platform quickly assesses a patient’s medical history, triages
a condition, digitally connects patients with clinicians, and predicts optimal treatment outcomes. EUDA’s holistic approach supports
patients throughout all stages of care, including wellness & prevention, urgent care & emergencies, pre-existing conditions,
and aftercare services.
Important
Information for Investors and Stockholders
This
announcement relates to a proposed transaction by EUDA and does not constitute an offer to sell or exchange, or the solicitation of an
offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or
exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Forward
Looking Statements
Certain
statements included in this press release are not historical facts but are forward-looking statements. Forward-looking statements generally
are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “expect,” “should,” “would,” “plan,”
“future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not
statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking
statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections
of market opportunity. These statements are based on various assumptions, whether or not identified in this press release and on
current expectations of EUDA’s management and are not predictions of actual performance. These forward-looking statements are provided
for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance,
a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible
to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of EUDA. Some important factors
that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and
foreign business, market, financial, political and legal conditions.
These
forward-looking statements are subject to a number of risks and uncertainties. These risks and uncertainties include, but are not limited
to, those factors described in the section entitled “Risk Factors” in the Annual Report filed with the SEC on June 28, 2023.
Important factors, among others, that may affect actual results or outcomes include: the inability of the parties to successfully or
timely consummate the transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject
to unanticipated conditions that could adversely affect EUDA or the expected benefits of the transaction, if not obtained; the failure
to realize the anticipated benefits of the transaction; matters discovered by EUDA as it complete its due diligence investigation of
the other parties; costs related to the transaction; the failure to satisfy the conditions to the consummation of the transaction; the
outcome of any legal proceedings that may be instituted against EUDA related to the transaction. Important factors that could cause EUDA’s
actual results or outcomes to differ materially from those discussed in the forward-looking statements include: EUDA’s ability
to manage growth; EUDA’s ability to execute its business plan; EUDA’s estimates of the size of the markets for its products
and services; the rate and degree of market acceptance of EUDA’s products and services; EUDA’s ability to identify and integrate
acquisitions; potential litigation involving EUDA or the validity or enforceability of intellectual property; and general economic and
market conditions impacting demand for EUDA’s products and services.
If
any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by
these forward-looking statements. There may be additional risks that EUDA presently know, or that EUDA currently believe are immaterial
that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements
reflect EUDA’s current expectations, plans and forecasts of future events and views as of the date hereof. Nothing in this press
release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking
statements in this press release, which speaks only as of the date they are made and are qualified in their entirety by reference to
the cautionary statements herein and the risk factors described above. EUDA anticipates that subsequent events and developments will
cause their assessments to change. However, while EUDA may elect to update these forward-looking statements at some point in the future,
it specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon
as representing EUDA’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should
not be placed upon the forward-looking statements.
Contact:
Christensen
Advisory
Roger
Hu
852.2232.3968
roger.hu@christensencomms.com
Euda Health (NASDAQ:EUDAW)
過去 株価チャート
から 10 2024 まで 11 2024
Euda Health (NASDAQ:EUDAW)
過去 株価チャート
から 11 2023 まで 11 2024